NCT07691697Toboroz
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
Outcomes After PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer: An Ambispective Multicenter Registry With a Prospective 1-10-Metastasis Cohort
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. szept. 17.
Rövid összefoglaló (regiszter, angolul)
PSMA-OLIGO-PRO is a multicenter, ambispective, observational real-world evidence registry of adults with metastatic hormone-sensitive or metastatic castration-resistant prostate cancer who develop a limited number of progressing metastatic lesions during active systemic therapy and are considered for comprehensive progression-directed radiotherapy (PDRT) in routine clinical care. The registry includes retrospective cases treated before June 26, 2026, and prospective cases enrolled from June 26, 2026, onward. Before the site-specific protocol amendment takes effect, the metastatic-lesion ceiling is 1-5. After the amendment takes effect, prospective candidates with 1-10 qualifying progressing metastatic lesions on baseline PSMA PET/CT or PSMA PET/MRI may be included. Metastatic burden is prespecified as 1-5 lesions, representing classical oligoprogression, or 6-10 lesions, representing exploratory, PSMA PET-defined, limited progression. Intraprostatic and prostate-bed progressing foci are recorded separately from the metastatic count and must also be included in the comprehensive PDRT plan. Otherwise eligible local-only episodes form a separate descriptive stratum. All qualifying metastatic and locally progressing sites must be deemed technically amenable to definitive-intent PDRT before prospective analytic-cohort enrollment. The registry does not assign imaging, systemic therapy, or radiotherapy; these clinical decisions are made independently by the treating team in routine care. A qualifying baseline PSMA PET and documentation of comprehensive treatability are required for inclusion. The primary endpoint is time to next systemic therapy in the continuation-plan treatment-start set. Key secondary outcomes include PDRT initiation and comprehensive implementation, time to widespread or non-PDRT-amenable progression, classical time to polymetastatic progression in the baseline 1-5 cohort, radiographic progression-free survival, lesion-level local control, overall survival, and treatment-related toxicity. The prespecified 1-5 versus 6-10 comparison is restricted to concurrent post-amendment prospective participants and is exploratory.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Megfigyeléses
- Résztvevők száma
- 1000 (tervezett)
- Első benyújtás
- 2026. jún. 28.
- Kezdés
- 2026. jún. 26.
- Elsődleges befejezés
- 2030. dec. 30.
- Fő szponzor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
- Betegségek
- Prosztatarák
- NCT-szám
- NCT07691697
Mit vállalsz
- Vizsgálat típusa: Megfigyeléses
- Tervezett résztvevők: 1000
- 2026. jún. 26. és az elsődleges befejezés (2030. dec. 30.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Radiotherapy delivered solely with palliative symptom-control intent rather than definitive progression-directed local-control intent.
Más betegség
- Diffuse, non-enumerable, or rapidly progressive disease that is not considered suitable for comprehensive lesion-directed radiotherapy.
Egyéb
- Limited progression defined only by conventional CT, MRI, or bone scintigraphy without a qualifying PSMA PET examination.
- More than five qualifying progressing metastatic lesions for retrospective or pre-amendment inclusion.
- More than 10 qualifying progressing metastatic lesions after amendment activation.
- Any known active metastatic or local progressing site that cannot be included in the comprehensive PDRT plan.
- Clinical deterioration or an urgent systemic-treatment indication that makes comprehensive PDRT inappropriate or unsafe.
- For prospective participation, inability to complete the approved consent process.
- For retrospective cases, missing baseline imaging or core dates such that metastatic burden, PDRT exposure, or at least one outcome or censoring time cannot be determined reliably.
A regiszterben nem jelölt feltételek
- Age 18 years or older.
- Histologically confirmed prostate adenocarcinoma.
- Metastatic hormone-sensitive or metastatic castration-resistant prostate cancer.
- Active systemic anticancer therapy at the qualifying limited-progression assessment.
- Qualifying baseline PSMA PET/CT or PSMA PET/MRI with review of relevant anatomical imaging.
- Metachronous, repeat, or induced oligoprogression or limited progression according to the protocol framework.
- Retrospective cases treated before June 26, 2026: 1-5 qualifying progressing metastatic lesions.
- Prospective cases enrolled before the site-specific amendment effective date: 1-5 qualifying progressing metastatic lesions.
- Prospective cases enrolled after the site-specific amendment effective date: 1-10 qualifying progressing metastatic lesions, prespecified as 1-5 or 6-10.
- Intraprostatic or prostate-bed progressing foci are recorded separately from the metastatic-lesion count and must also be technically amenable to comprehensive PDRT.
- Every qualifying metastatic and local progressing site is judged technically amenable to comprehensive definitive-intent PDRT before prospective analytic-cohort enrollment.
- For post-amendment prospective enrollment, qualifying PSMA PET performed within 60 days before enrollment and index PDRT planned to begin within 60 days after the scan.
- Availability of the qualifying PET date, systemic-therapy dates, locked metastatic-lesion count, separate local-site count, lesion map, and eligibility decision. For retrospective inclusion, PDRT exposure and at least one outcome or censoring time must also be determinable.
Életkor a regiszterben: 18 év – - · Nem: csak férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Affidea Nu-Med Cancer Diagnostics and Therapy Center Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát | Zamość | Lengyelország | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.